ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma

This study is ongoing, but not recruiting participants.
Study NCT00057980.   Last updated on July 23, 2008.   Information provided by National Cancer Institute (NCI)

This Tabular View shows the required WHO registration data elements as marked by

Descriptive Information Fields
Brief Title  Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma
Official Title  Phase I/II Study of Epirubicin and Celecoxib for Hepatocellular Carcinoma
Brief Summary

RATIONALE: Celecoxib may stop the growth of tumor cells by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining celecoxib with epirubicin may kill more tumor cells.

PURPOSE: This phase I/II trial is studying the side effects and best dose of epirubicin when given together with celecoxib and to see how well it works in treating patients with hepatocellular carcinoma (liver cancer).

Detailed Description

OBJECTIVES:

  • Determine the maximum tolerated dose of epirubicin when administered with celecoxib in patients with hepatocellular carcinoma.
  • Determine the response rate in patients treated with this regimen.
  • Determine the 6-month and overall survival of patients treated with this regimen.
  • Determine the toxicity profile of this regimen in these patients.
  • Determine the effects of this regimen on serum levels of vascular endothelial growth factor and correlate these effects with response in these patients.
  • Correlate the expression of cyclooxygenase-2 in tumor tissue and nonmalignant liver tissue with response in patients treated with this regimen.

OUTLINE: This is a dose-escalation study of epirubicin.

  • Phase I:Patients receive epirubicin IV over 20 minutes on day 1 and oral celecoxib twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-5 patients receive escalating doses of epirubicin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 3 of 5 patients experience dose-limiting toxicity.

  • Phase II: Additional patients are accrued and treated as in phase I at the MTD of epirubicin.

Patients are followed every 3 months.

PROJECTED ACCRUAL: A total of 3-52 patients (3-15 for phase I and 12-37 for phase II) will be accrued for this study.

Study Phase Phase I, Phase II
Study Type  Interventional
Study Design  Treatment
Primary Outcome Measure  Maximum tolerated dose of epirubicin [ Designated as safety issue: Yes ]
Response rate [ Designated as safety issue: No ]
Survival at 6 months [ Designated as safety issue: No ]
Overall survival [ Designated as safety issue: No ]
Secondary Outcome Measure  Toxicity profile [ Designated as safety issue: Yes ]
Serum vascular endothelial growth factor levels in correlation to response [ Designated as safety issue: No ]
Cyclooxygenase-2 expression in tumor tissue and nonmalignant liver tissue in correlation to response [ Designated as safety issue: No ]
Condition  Liver Cancer
Intervention  Drug: celecoxib
Drug: epirubicin hydrochloride
MEDLINE PMIDs
Links Clinical trial summary from the National Cancer Institute's PDQ® database This link exits the ClinicalTrials.gov site
Recruitment Information Fields
Recruitment Status  Active, not recruiting
Enrollment 
Start Date  October 2002
Completion Date
Eligibility Criteria 

DISEASE CHARACTERISTICS:

  • Diagnosis of localized or metastatic hepatocellular carcinoma (HCC) by 1 of the following:

    • Biopsy
    • Alpha-fetoprotein (AFP) measurement (greater than 400 ng/mL if hepatitis B surface antigen [HBsAg] is negative OR greater than 1,000 ng/mL if HBsAg is positive)
  • Not amenable to surgical resection or liver-directed therapy
  • Measurable or evaluable disease* NOTE: *Changes in AFP alone are not sufficient
  • Child-Pugh score A or B

PATIENT CHARACTERISTICS:

Age

  • 18 and over

Performance status

  • ECOG 0-2

Life expectancy

  • At least 12 weeks

Hematopoietic

  • Absolute neutrophil count at least 1,500/mm^3
  • Platelet count at least 75,000/mm^3

Hepatic

  • Bilirubin no greater than 3.0 mg/dL
  • AST no greater than 5 times upper limit of normal

Renal

  • Creatinine no greater than 2.0 mg/dL

Cardiovascular

  • LVEF greater than 45% by MUGA or echocardiogram

Other

  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • No requirement for nonsteroidal anti-inflammatory drugs (NSAIDs) except low-dose (81 mg) aspirin
  • No known hypersensitivity to aspirin or other NSAIDs
  • No contraindication to cyclooxygenase-2 (COX-2) inhibitor therapy

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • Not specified

Chemotherapy

  • Not specified

Endocrine therapy

  • Not specified

Radiotherapy

  • Not specified

Surgery

  • Not specified

Other

  • No prior therapy for HCC
Gender Both
Ages 18 Years and older
Accepts Healthy Volunteers No
Contacts ††
Location Countries  United States
Administrative Information Fields
NCT ID  NCT00057980
Organization ID CDR0000285669
Secondary IDs †† NU-02I6
Study Sponsor  Robert H. Lurie Cancer Center
Collaborators †† National Cancer Institute (NCI)
Investigators 
Study Chair:     Mary Mulcahy, MD     Robert H. Lurie Cancer Center    
Information Provided By National Cancer Institute (NCI)
Verification Date January 2006
First Received Date  April 7, 2003
Last Updated Date July 23, 2008

 †    Required WHO trial registration data element.
††   WHO trial registration data element that is required only if it exists.




Links to all studies - primarily for crawlers